Trial Profile
An Open Label Study of the Chronic and Acute Effects of Pitavastatin on Monocyte Phenotype, Endothelial Dysfunction and HDL Atheroprotective Function in Subjects With Metabolic Syndrome (CAPITAIN)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jul 2013
Price :
$35
*
At a glance
- Drugs Pitavastatin (Primary)
- Indications Atherosclerosis; Metabolic syndrome
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms CAPITAIN
- Sponsors Kowa Research Institute
- 16 May 2012 New trial record